The DOI matches its Crossref record; 39 of the 44 references it cites were found in a registry or an index.
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
Open accessAbstract
Importance: Cerebrospinal fluid phosphorylated tau (p-tau) 181, p-tau217, and p-tau231 are associated with neuropathological outcomes, but a comparison of these p-tau isoforms in blood samples is needed. Objective: To conduct a head-to-head comparison of plasma p-tau181 and p-tau231 measured on the single-molecule array (Simoa) platform and p-tau181 and p-tau217 measured on the Meso Scale Discovery (MSD) platform on amyloid and tau positron emission tomography (PET) measures, neurodegeneration, vascular pathology, and cognitive outcomes. Design, Setting, and Participants: This study included data from the Mayo Clinic Study on Aging collected from March 1, 2015, to September 30, 2017, and analyzed between December 15, 2020, and May 17, 2021. Associations between the 4 plasma p-tau measures and dichotomous amyloid PET, metaregion of interest tau PET, and entorhinal cortex tau PET were analyzed using logistic regression models; the predictive accuracy was summarized using area under the receiver operating characteristic curve (AUROC) statistic. Of 1329 participants without dementia and with p-tau181 and p-tau217 on MSD, 200 participants with plasma p-tau181 and p-tau231 on Simoa and magnetic resonance imaging and amyloid and tau PET data at the same study visit were eligible. Main Outcomes And Measures: Primary outcomes included amyloid (greater than 1.48 standardized uptake value ratio) and tau PET, white matter hyperintensities, white matter microstructural integrity (fractional anisotropy genu of corpus callosum and hippocampal cingulum bundle), and cognition. Results: Of 200 included participants, 101 (50.5%) were male, and the median (interquartile range [IQR]) age was 79.5 (71.1-84.1) years. A total of 177 were cognitively unimpaired (CU) and 23 had mild cognitive impairment. Compared with amyloid-negative CU participants, among amyloid-positive CU participants, the median (IQR) Simoa p-tau181 measure was 49% higher (2.58 [2.00-3.72] vs 1.73 [1.45-2.13] pg/mL), MSD p-tau181 measure was 53% higher (1.22 [0.91-1.56] vs 0.80 [0.66-0.97] pg/mL), MSD p-tau217 measure was 77% higher (0.23 [0.17-0.34] vs 0.13 [0.09-0.18] pg/mL), and Simoa p-tau231 measure was 49% higher (20.21 [15.60-25.41] vs 14.27 [11.27-18.10] pg/mL). There were no differences between the p-tau species for amyloid PET and tau PET metaregions of interest. However, among CU participants, both MSD p-tau181 and MSD p-tau217 more accurately predicted abnormal entorhinal cortex tau PET than Simoa p-tau181 (MSD p-tau181: AUROC, 0.80 vs 0.70; P = .046; MSD p-tau217: AUROC, 0.81 vs 0.70; P = .04). MSD p-tau181 and p-tau217 and Simoa p-tau181, but not p-tau231, were associated with greater white matter hyperintensity volume and lower white matter microstructural integrity. Conclusions and Relevance: In this largely presymptomatic population, these results suggest subtle differences across plasma p-tau species and platforms for the prediction of amyloid and tau PET and magnetic resonance imaging measures of cerebrovascular and Alzheimer-related pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Detection of Aβ positivity using mass spectrometry %p-tau217 in cognitively normal cohorts appears better than what has been reported when using plasma p-tau217 immunoassays, although this must be confirmed in head-to-head studies22,23,48–50.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [48]
In the citing paper
“Plasma ptau-217 has repeatedly demonstrated strong prognostic performance and generally outperforms other plasma biomarkers in predicting conversion from MCI to dementia (20,24).”
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationJack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
Self-citationDefining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
Self-citationRoberts, R. O., Geda, Y. E., Knopman, D. S., Cha, R. H., Pankratz, V. S., Boeve, B. F., Ivnik, R. J., Tangalos, E. G., Petersen, R. C., & Rocca, W. A. (2008) · Neuroepidemiology · doi:10.1159/000115751 · Cited by 797
Self-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Self-citationKinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B
Price, J. C., Klunk, W. E., Lopresti, B. J., Lu, X., Hoge, J. A., Ziolko, S. K., Holt, D. P., MELTZER, C. C., DeKosky, S. T., & Mathis, C. A. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600146 · Cited by 723
Cited by
Sorted by citations
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
Self-citationHansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., Salloway, S., Sperling, R., Zetterberg, H., & Teunissen, C. E. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12756 · Cited by 607
Self-citationTau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., et al. (2023) · Brain · doi:10.1093/brain/awac333 · Cited by 522
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationPathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Performance of plasma phosphorylated tau 181 and 217 in the community
Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01822-2 · Cited by 465
Self-citationBarthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448
“Detection of Aβ positivity using mass spectrometry %p-tau217 in cognitively normal cohorts appears better than what has been reported when using plasma p-tau217 immunoas-says, although this must be confirmed in head-to-head studies 22,23,48–50 .”
MethodBlood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Karikari, T. K., Ashton, N. J., Brinkmalm, G., Brum, W. S., Benedet, A. L., Montoliu‐Gaya, L., Lantero‐Rodriguez, J., Pascoal, T. A., Suárez‐Calvet, M., Rosa‐Neto, P., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00665-2 · Cited by 333
Self-citationHampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283
Self-citationEmerging ELISA derived technologies for in vitro diagnostics
Peng, P., Liu, C., Li, Z., Xue, Z., Mao, P., Hu, J., Xu, F., Yao, C., & You, M. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116605 · Cited by 278
Therriault, J., Vermeiren, M. R., Servaes, S., Tissot, C., Ashton, N. J., Benedet, A. L., Karikari, T. K., Lantero‐Rodriguez, J., Brum, W. S., Lussier, F. Z., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4485 · Cited by 278
Self-citationCSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02443-z · Cited by 249
Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change
Smirnov, D. S., Ashton, N. J., Blennow, K., Zetterberg, H., Simrén, J., Lantero‐Rodriguez, J., Karikari, T. K., Hiniker, A. O., Rissman, R. A., Salmon, D. P., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02408-5 · Cited by 231
Self-citationPlasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
González‐Ortiz, F., Kac, P. R., Brum, W. S., Zetterberg, H., Blennow, K., & Karikari, T. K. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00605-8 · Cited by 235
Self-citationSpecific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202217123 · Cited by 205
Self-citationBiomarker-based staging of Alzheimer disease: rationale and clinical applications
Therriault, J., Schindler, S. E., Salvadó, G., Pascoal, T. A., Benedet, A. L., Ashton, N. J., Karikari, T. K., Apostolova, L. G., Murray, M. E., Verberk, I. M. W., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00942-2 · Cited by 225
Self-citationBayoumy, S., Verberk, I. M. W., den Dulk, B., Hussainali, Z., Zwan, M. D., van der Flier, W. M., Ashton, N. J., Zetterberg, H., Blennow, K., Vanbrabant, J., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00939-9 · Cited by 196
Self-citationPalmqvist, S., Whitson, H. E., Allen, L. A., Suárez‐Calvet, M., Galasko, D., Karikari, T. K., Okrahvi, H. R., Paczynski, M., Schindler, S. E., Teunissen, C. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70535 · Cited by 220
Self-citationJanelidze, S., Barthélemy, N. R., He, Y., Bateman, R. J., & Hansson, O. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.0199 · Cited by 176
An accurate fully automated panel of plasma biomarkers for Alzheimer's disease
Palmqvist, S., Stomrud, E., Cullen, N. C., Janelidze, S., Manuilova, E., Jethwa, A., Bittner, T., Eichenlaub, U., Suridjan, I., Kollmorgen, G., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12751 · Cited by 166
Self-citationBarthélemy, N. R., Saef, B., Li, Y., Gordon, B. A., He, Y., Horie, K., Stomrud, E., Salvadó, G., Janelidze, S., Sato, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00380-7 · Cited by 153
Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151
Predicting amyloid PET and tau PET stages with plasma biomarkers
Jack, C. R., Wiste, H. J., Algeciras‐Schimnich, A., Figdore, D. J., Schwarz, C. G., Lowe, V. J., Ramanan, V. K., Vemuri, P., Mielke, M. M., Knopman, D. S., et al. (2023) · Brain · doi:10.1093/brain/awad042 · Cited by 154
Self-citationSchindler, S. E., Karikari, T. K., Ashton, N. J., Henson, R. L., Yarasheski, K. E., West, T., Meyer, M. R., Kirmess, K. M., Li, Y., Saef, B. A., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200358 · Cited by 141
Self-citationA comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests
Warmenhoven, N., Salvadó, G., Janelidze, S., Mattsson, N., Bali, D., Dolado, A. O., Kolb, H. C., Triana‐Baltzer, G., Barthélemy, N. R., Schindler, S. E., et al. (2024) · Brain · doi:10.1093/brain/awae346 · Cited by 157
Self-citationAngioni, D., Delrieu, J., Hansson, O., Fillit, H. M., Aisen, P. S. S., Cummings, J. L., Sims, J. R., Braunstein, J. B., Sabbagh, M. N., Bittner, T., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.85 · Cited by 129
Self-citationPlasma phosphorylated tau 217 in preclinical Alzheimer’s disease
Jonaitis, E. M., Janelidze, S., Cody, K. A., Langhough, R., Du, L., Chin, N. A., Mattsson-Carlgren, N., Hogan, K. J., Christian, B. T., Betthauser, T. J., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad057 · Cited by 124
Meyer, M. R., Kirmess, K. M., Eastwood, S., Wente‐Roth, T. L., Irvin, F., Holubasch, M. S., Venkatesh, V., Fogelman, I., Monane, M., Hanna, L., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13764 · Cited by 130
Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00405-1 · Cited by 122
Self-citationGroot, C., Cicognola, C., Bali, D., Triana‐Baltzer, G., Dage, J. L., Pontecorvo, M. J., Kolb, H. C., Ossenkoppele, R., Janelidze, S., & Hansson, O. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01005-8 · Cited by 93
Self-citationMendes, A. J., Ribaldi, F., Lathuilière, A., Ashton, N. J., Janelidze, S., Zetterberg, H., Scheffler, M., Assal, F., Garibotto, V., Blennow, K., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-023-12148-5 · Cited by 112
Self-citationConsiderations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 109
Self-citationAshton, N. J., Keshavan, A., Brum, W. S., Andréasson, U., Arslan, B., Droescher, M., Barghorn, S., Vanbrabant, J., Lambrechts, C., Loo, M. V., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14508 · Cited by 100
Self-citationShun, H., Zhang, L., Su, Y., Liang, X., Yang, J., Luo, Q., & Luo, H. (2024) · Science Advances · doi:10.1126/sciadv.abm3088 · Cited by 98
Planche, V., Bouteloup, V., Pellegrin, I., Mangin, J., Dubois, B., Ousset, P., Pasquier, F., Blanc, F., Paquet, C., Hanon, O., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201479 · Cited by 98
Plasma p‐tau immunoassays in clinical research for Alzheimer's disease
Teunissen, C. E., Kolster, R., Triana‐Baltzer, G., Janelidze, S., Zetterberg, H., & Kolb, H. C. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14397 · Cited by 96
Self-citationEffectiveness of Therapeutic Gardens for People with Dementia: A Systematic Review
Murroni, V., Cavalli, R., Basso, A., Borella, E., Meneghetti, C., Melendugno, A., & Pazzaglia, F. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18189595 · Cited by 94
Iaccarino, L., Burnham, S. C., Dell’Agnello, G., Dowsett, S. A., & Epelbaum, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.43 · Cited by 87
Yu, L., Boyle, P. A., Janelidze, S., Petyuk, V., Wang, T., Bennett, D. A., Hansson, O., & Schneider, J. A. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02570-4 · Cited by 84
Moloney, C. M., Labuzan, S. A., Crook, J. E., Siddiqui, H., Castanedes‐Casey, M., Lachner, C., Petersen, R. C., Duara, R., Graff‐Radford, N. R., Dickson, D. W., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12749 · Cited by 76
Self-citationDiagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
Kac, P. R., Gonzalez-Ortiz, F., Simrén, J., Dewit, N., Vanmechelen, E., Zetterberg, H., Blennow, K., Ashton, N. J., & Karikari, T. K. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01011-w · Cited by 73
Self-citationZeng, X., Chen, Y., Sehrawat, A., Lee, J., Lafferty, T. K., Kofler, J., Berman, S., Sweet, R. A., Tudorascu, D., Klunk, W. E., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00711-1 · Cited by 79
Self-citationPlasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease
Salvadó, G., Janelidze, S., Bali, D., Dolado, A. O., Therriault, J., Brum, W. S., Binette, A. P., Stomrud, E., Mattsson, N., Palmqvist, S., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.3217 · Cited by 88
Self-citationKivisäkk, P., Fatima, H. A., Cahoon, D. S., Otieno, B. A., Chacko, L., Minooei, F., Demos, C., Stengelin, M. K., Sigal, G. B., Wohlstadter, J. N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51334-x · Cited by 64
Alzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 78
Zetterberg, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12618 · Cited by 59
Self-citationPlasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
Doré, V., Doecke, J. D., Saad, Z. S., Triana‐Baltzer, G., Slemmon, R., Krishnadas, N., Bourgeat, P., Huang, K., Burnham, S. C., Fowler, C. J., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12307 · Cited by 56
Mohs, R. C., Beauregard, D., Dwyer, J., Gaudioso, J., Bork, J., MaGee‐Rodgers, T., Key, M. N., Kerwin, D. R., Hughes, L., Cordell, C. B., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13722 · Cited by 60
Biofluid Biomarkers of Alzheimer’s Disease: Progress, Problems, and Perspectives
Huang, S., Wang, Y., & Guo, J. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00836-7 · Cited by 63
Murray, M. E., Moloney, C. M., Kouri, N., Syrjanen, J. A., Matchett, B. J., Rothberg, D. M., Tranovich, J. F., Sirmans, T. N. H., Wiste, H. J., Boon, B. D. C., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00578-0 · Cited by 58
Self-citationBlood biomarkers for Alzheimer's disease and related disorders
Zetterberg, H., & Schott, J. M. (2022) · Acta Neurologica Scandinavica · doi:10.1111/ane.13628 · Cited by 55
Self-citationAguillon, D., Langella, S., Chen, Y., Sanchez, J. S., Su, Y., Vila‐Castelar, C., Vasquez, D., Zetterberg, H., Hansson, O., Dage, J. L., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12906 · Cited by 54
Self-citationPerformance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
Wilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01116-2 · Cited by 51
Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review
Hardy-Sosa, A., León‐Arcia, K., Llibre‐Guerra, J. J., Berlanga‐Acosta, J., Baez, S. D. L. C., Guillén, G. E., & Valdes-Sosa, P. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.683689 · Cited by 57
Kac, P. R., González‐Ortiz, F., Emeršič, A., Dulewicz, M., Koutarapu, S., Turton, M., An, Y., Smirnov, D. S., Kulczyńska‐Przybik, A., Varma, V. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46876-7 · Cited by 56
Self-citationSatpathi, S., Reid, R. I., Przybelski, S. A., Raghavan, S., Cogswell, P. M., Meyer, N. K., Lowe, V. J., Gunter, J. L., Petersen, R. C., Jack, C. R., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01842-3 · Cited by 48
Self-citationPromising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update
Park, S. A., Jang, Y. J., Kim, M. K., Lee, S. M., & Moon, S. Y. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.4.401 · Cited by 47
Biomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 52
Domínguez-Fernández, C., Egiguren-Ortiz, J., Razquin, J., Gómez-Galán, M., Heras-García, L. D. L., Paredes-Rodriguez, E., Astigarraga, E., Miguélez, C., & Barreda‐Gómez, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043321 · Cited by 52
A head‐to‐head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
Anastasi, F., Fernández‐Lebrero, A., Ashton, N. J., Ortiz‐Romero, P., Torres‐Torronteras, J., González‐Escalante, A., Milà‐Alomà, M., Contador, J., García‐Escobar, G., Manero-Borràs, R. M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14609 · Cited by 49
Self-citationAsken, B. M., Tanner, J. A., VandeVrede, L., Mantyh, W. G., Casaletto, K. B., Staffaroni, A. M., La Joie, R., Iaccarino, L., Soleimani-Meigooni, D., Rojas, J. C., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200678 · Cited by 40
Plasma tau biomarkers for biological staging of Alzheimer’s disease
Montoliu‐Gaya, L., Salvadó, G., Therriault, J., Nilsson, J., Janelidze, S., Weiner, S., Ashton, N. J., Benedet, A. L., Rahmouni, N., Lantero‐Rodriguez, J., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00951-w · Cited by 48
Self-citationEgroo, M. V., Riphagen, J. M., Ashton, N. J., Janelidze, S., Sperling, R. A., Johnson, K. A., Yang, H., Bennett, D. A., Blennow, K., Hansson, O., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02041-y · Cited by 46
Self-citationWang, J., Huang, Q., Chen, X., You, Z., He, K., Guo, Q., Huang, Y. H., Yang, Y., Lin, Z., Guo, T., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02501-z · Cited by 46
Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies
Diaz‐Galvan, P., Przybelski, S. A., Algeciras‐Schimnich, A., Figdore, D. J., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Jack, C. R., Min, H.-K. P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13653 · Cited by 43
Self-citationAlzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 55
Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET
Cogswell, P. M., Lundt, E. S., Therneau, T. M., Wiste, H. J., Graff‐Radford, J., Algeciras‐Schimnich, A., Lowe, V. J., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13539 · Cited by 38
Self-citationArias, J. F., Brum, W. S., Salvadó, G., Therriault, J., Servaes, S., Wang, Y., Aumont, É., Rahmouni, N., Macedo, A. C., Quispialaya, K. M., et al. (2025) · Brain · doi:10.1093/brain/awaf033 · Cited by 41
Self-citationMultimodal comparisons of QSM and PET in neurodegeneration and aging
Cogswell, P. M., & Fan, A. P. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120068 · Cited by 38
Xiao, Z., Wu, W., Ma, X., Wu, J., Liang, X., Zhou, X., Cao, Y., Zhao, Q., & Ding, D. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12514 · Cited by 37
Pahlke, S. C., Kahale, L. A., Mahinrad, S., Sousa‐Pinto, B., Vieira, R. J., McAteer, M. B., Claessen, T., Contador, J., Hofmann, A., Kuchenbecker, L. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70828 · Cited by 42
Self-citationHonig, L. S., Kang, M. S., Lee, A., Reyes‐Dumeyer, D., Piriz, A. L., Soriano, B., Franco, Y., Coronado, Z. D., Recio, P., Mejía, D. R., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.8214 · Cited by 33
Self-citationPlasma ATN(I) classification and precision pharmacology in Alzheimer's disease
Imbimbo, B. P., Watling, M., Imbimbo, C., & Nisticò, R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13084 · Cited by 34
Blood-based biomarkers in Alzheimer’s disease: a mini-review
Padala, S. P., & NEWHOUSE, P. A. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01114-1 · Cited by 39
Jarek, D. J., Mizerka, H., Nuszkiewicz, J., & Szewczyk‐Golec, K. (2024) · Biomedicines · doi:10.3390/biomedicines12040786 · Cited by 37
Vila‐Castelar, C., Chen, Y., Langella, S., Lopera, F. J., Zetterberg, H., Hansson, O., Dage, J. L., Janelidzde, S., Su, Y., Chen, K., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13314 · Cited by 35
Self-citationP-tau217 in Alzheimer’s disease
Telser, J., Risch, L., Saely, C. H., Grossmann, K., & Werner, P. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.03.018 · Cited by 32
Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease
Brickman, A. M., Manly, J. J., Honig, L. S., Sanchez, D. L., Reyes‐Dumeyer, D., Lantigua, R., Vonsattel, J. P., Teich, A. F., Kang, M. S., Dage, J. L., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51529 · Cited by 32
Self-citationA critical appraisal of blood-based biomarkers for Alzheimer’s disease
Lista, S., Mapstone, M. E., Caraci, F., Emanuele, E., López‐Ortiz, S., Martín-Hernández, J., Triaca, V., Imbimbo, C., Gabelle, A., Mielke, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102290 · Cited by 30
Self-citationPhospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
Meyer, S. D., Vanbrabant, J., Schaeverbeke, J. M., Reinartz, M., Luckett, E. S., Dupont, P. J., Laere, K. V., Stoops, E., Vanmechelen, E., Poesen, K., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51553 · Cited by 32
Self-citationMorrison, M. S., Aparicio, H. J., Blennow, K., Zetterberg, H., Ashton, N. J., Karikari, T. K., Tripodis, Y., Martin, B. M., Palmisano, J. N., Sugarman, M. A., et al. (2022) · Brain · doi:10.1093/brain/awac175 · Cited by 32
Self-citation11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous
Abrahamson, E. E., Kofler, J., Becker, C. R., Price, J. C., Newell, K. L., Ghetti, B. F., Murrell, J. R., McLean, C., López, O. L., Mathis, C. A., et al. (2021) · Brain · doi:10.1093/brain/awab434 · Cited by 28
Burnham, S. C., Iaccarino, L., Pontecorvo, M. J., Fleisher, A., Lu, M., Collins, E. C., & Devous, M. D. (2023) · Brain Communications · doi:10.1093/braincomms/fcad305 · Cited by 30
Pilotto, A., Parigi, M., Bonzi, G., Battaglio, B., Ferrari, E., Mensi, L., Benussi, A., Caratozzolo, S., Cosseddu, M., Turrone, R., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215646 · Cited by 28
Self-citationMuir, R. T., Ismail, Z., Black, S. E., & Smith, E. E. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13510 · Cited by 27
Comorbidities confound Alzheimer’s blood tests
Schindler, S. E., & Karikari, T. K. (2022) · Nature Medicine · doi:10.1038/s41591-022-01875-3 · Cited by 27
Self-citationEffects of certain pre-analytical factors on the performance of plasma phospho-tau217
Bali, D., Hansson, O., & Janelidze, S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01391-1 · Cited by 31
Antonioni, A., Raho, E. M., Lorenzo, F. D., Manzoli, L., Flacco, M. E., & Koch, G. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12996-3 · Cited by 34
Ravichandran, S., Snyder, P. J., Alber, J., Murchison, C., Chaby, L. E., Jeromin, A., & Arthur, E. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01668-5 · Cited by 28
Self-citationMRI and fluid biomarkers reveal determinants of myelin and axonal loss with aging
Walker, K. A., Duggan, M. R., Gong, Z., Dark, H. E., Laporte, J. P., Faulkner, M. E., An, Y., Lewis, A., Moghekar, A., Resnick, S. M., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51730 · Cited by 25
Temporal Dynamics and Biological Variability of Alzheimer Biomarkers
Yun, J., Shin, D., Lee, E. H., Kim, J. P., Ham, H., Gu, Y., Chun, M. Y., Kang, S. H., Kim, Y. J., Na, D. L., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2024.5263 · Cited by 32
Self-citationPan, F., Huang, L., Wang, Y., Huang, Q., Guan, Y., Li, Y., Xie, F., & Guo, Q. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70987 · Cited by 30
Tau proteins in blood as biomarkers of Alzheimer’s disease and other proteinopathies
Verde, F. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02471-y · Cited by 26
Manolopoulos, A., Delgado‐Peraza, F., Mustapić, M., Pucha, K. A., Nogueras‐Ortiz, C. J., Daskalopoulos, A., Knight, D. D., Leoutsakos, J., Oh, E. S., Lyketsos, C. G., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1254834 · Cited by 26
Álvarez‐Sánchez, L., Peña‐Bautista, C., Baquero, M., & Cháfer‐Pericás, C. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215093 · Cited by 25
Grasset, L., Bouteloup, V., Cacciamani, F., Pellegrin, I., Planche, V., Chêne, G., Dufouil, C., & for the MEMENTO study group (2024) · Neurology · doi:10.1212/wnl.0000000000209307 · Cited by 23
Wang, J., Lu, X., & He, Y. (2025) · Biosensors · doi:10.3390/bios15020085 · Cited by 24
Plasma NfL and GFAP for predicting VCI and related brain changes in community and clinical cohorts
Raghavan, S., Graff‐Radford, J., Hofrenning, E. I., Fought, A. J., Reid, R. I., Kamykowski, M. G., Algeciras‐Schimnich, A., Windham, B. G., Knopman, D. S., Lowe, V. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70381 · Cited by 22
Self-citationMcCarter, S. J., Lesnick, T. G., Lowe, V. J., Rabinstein, A. A., Przybelski, S. A., Algeciras‐Schimnich, A., Ramanan, V. K., Jack, C. R., Petersen, R. C., Knopman, D. S., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220158 · Cited by 22
Self-citation
Metadata
- Authors
- Mielke, M. M., Frank, R. D., Dage, J. L., Jeromin, A., Ashton, N. J., Blennow, K., Karikari, T. K., Vanmechelen, E., Zetterberg, H., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- Eli Lilly (United States) (US)
- Cohen Veterans Bioscience (US)
- King's College London (GB)
- Sahlgrenska University Hospital (SE)
- University of Gothenburg (SE)
- ADx Neurosciences, Ghent, Belgium
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
- Mayo Clinic in Florida (US)
- Department of Neurology, Mayo Clinic, Rochester, Minnesota
- Corresponding author
- Mielke, Michelle M.
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2021-09-01
- Volume
- 78
- Issue
- 9
- Pages
- 1108
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC8314178
- OpenAlex
- W3183927686
- Cited by
- 244
- References
- 44
- Citations by year
- 2026: 33 · 2025: 58 · 2024: 50 · 2023: 48 · 2022: 48 · 2021: 6
- FWCI
- 27.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- European Commission (860197)
- Vetenskapsrådet (2017-00915)
- National Institutes of Health
- National Institute on Aging (U01AG006786, R01AG011378, R01AG041851, R37AG011378, P30AG062677)
- National Institute of Neurological Disorders and Stroke (R01NS097495)
- H2020 European Research Council (681712)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- phosphorylated tau, plasma biomarkers, p-tau181, p-tau217, p-tau231, amyloid PET, tau PET, amyloid-beta, neurodegeneration, white matter hyperintensities, fractional anisotropy, cognitive impairment, Simoa, MSD, Alzheimer's disease, vascular pathology
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cross-Sectional Studies, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Nerve Degeneration, Phosphorylation, Biomarkers, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
